vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与Safehold Inc.（SAFE）财务数据对比。点击上方公司名可切换其他公司
Safehold Inc.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.3倍（$97.9M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 6.5%），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 2.5%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
SAFE投资有限公司是一家位于中国香港的中国主权财富基金，主要承担主权财富相关的投资运营职能，依托香港的国际金融中心优势开展相关投资业务。
PBYI vs SAFE — 直观对比
营收规模更大
SAFE
是对方的1.3倍
$75.5M
营收增速更快
PBYI
高出21.2%
6.5%
两年增速更快
PBYI
近两年复合增速
2.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $97.9M |
| 净利润 | — | $27.9M |
| 毛利率 | 69.3% | 98.6% |
| 营业利润率 | 22.7% | 27.4% |
| 净利率 | — | 28.5% |
| 营收同比 | 27.7% | 6.5% |
| 净利润同比 | — | 7.1% |
| 每股收益（稀释后） | $0.26 | $0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYISAFE
| Q4 25 | $75.5M | $97.9M | ||
| Q3 25 | $54.5M | $96.2M | ||
| Q2 25 | $52.4M | $93.8M | ||
| Q1 25 | $46.0M | $97.7M | ||
| Q4 24 | $59.1M | $91.9M | ||
| Q3 24 | $80.5M | $90.7M | ||
| Q2 24 | $47.1M | $89.9M | ||
| Q1 24 | $43.8M | $93.2M |
净利润PBYISAFE
| Q4 25 | — | $27.9M | ||
| Q3 25 | $8.8M | $29.3M | ||
| Q2 25 | $5.9M | $27.9M | ||
| Q1 25 | $3.0M | $29.4M | ||
| Q4 24 | — | $26.0M | ||
| Q3 24 | $20.3M | $19.3M | ||
| Q2 24 | $-4.5M | $29.7M | ||
| Q1 24 | $-4.8M | $30.7M |
毛利率PBYISAFE
| Q4 25 | 69.3% | 98.6% | ||
| Q3 25 | 77.7% | 98.5% | ||
| Q2 25 | 76.5% | 99.1% | ||
| Q1 25 | 77.1% | 98.8% | ||
| Q4 24 | 76.4% | 98.8% | ||
| Q3 24 | 63.9% | 98.8% | ||
| Q2 24 | 77.4% | 98.8% | ||
| Q1 24 | 75.5% | 98.8% |
营业利润率PBYISAFE
| Q4 25 | 22.7% | 27.4% | ||
| Q3 25 | 17.6% | 25.9% | ||
| Q2 25 | 12.7% | 25.5% | ||
| Q1 25 | 8.7% | 25.9% | ||
| Q4 24 | 22.6% | 24.6% | ||
| Q3 24 | 27.4% | 17.5% | ||
| Q2 24 | -4.6% | 26.7% | ||
| Q1 24 | -5.3% | 26.4% |
净利率PBYISAFE
| Q4 25 | — | 28.5% | ||
| Q3 25 | 16.2% | 30.5% | ||
| Q2 25 | 11.2% | 29.8% | ||
| Q1 25 | 6.5% | 30.1% | ||
| Q4 24 | — | 28.3% | ||
| Q3 24 | 25.2% | 21.3% | ||
| Q2 24 | -9.6% | 33.0% | ||
| Q1 24 | -11.0% | 33.0% |
每股收益（稀释后）PBYISAFE
| Q4 25 | $0.26 | $0.38 | ||
| Q3 25 | $0.17 | $0.41 | ||
| Q2 25 | $0.12 | $0.39 | ||
| Q1 25 | $0.06 | $0.41 | ||
| Q4 24 | $0.40 | $0.36 | ||
| Q3 24 | $0.41 | $0.27 | ||
| Q2 24 | $-0.09 | $0.42 | ||
| Q1 24 | $-0.10 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $21.7M |
| 总债务越低越好 | $22.7M | $4.6B |
| 股东权益账面价值 | $130.3M | $2.4B |
| 总资产 | $216.3M | $7.2B |
| 负债/权益比越低杠杆越低 | 0.17× | 1.90× |
8季度趋势，按日历期对齐
现金及短期投资PBYISAFE
| Q4 25 | $97.5M | $21.7M | ||
| Q3 25 | $94.4M | $12.1M | ||
| Q2 25 | $96.0M | $13.9M | ||
| Q1 25 | $93.2M | $17.3M | ||
| Q4 24 | $101.0M | $8.3M | ||
| Q3 24 | $96.7M | $15.6M | ||
| Q2 24 | $96.8M | $13.4M | ||
| Q1 24 | $107.2M | $11.3M |
总债务PBYISAFE
| Q4 25 | $22.7M | $4.6B | ||
| Q3 25 | $34.0M | $4.5B | ||
| Q2 25 | $45.3M | $4.4B | ||
| Q1 25 | $56.7M | $4.3B | ||
| Q4 24 | $68.0M | $4.3B | ||
| Q3 24 | $79.3M | $4.3B | ||
| Q2 24 | $90.7M | $4.2B | ||
| Q1 24 | $102.0M | $4.1B |
股东权益PBYISAFE
| Q4 25 | $130.3M | $2.4B | ||
| Q3 25 | $115.3M | $2.4B | ||
| Q2 25 | $104.7M | $2.4B | ||
| Q1 25 | $97.1M | $2.4B | ||
| Q4 24 | $92.1M | $2.3B | ||
| Q3 24 | $71.1M | $2.3B | ||
| Q2 24 | $48.5M | $2.3B | ||
| Q1 24 | $51.0M | $2.3B |
总资产PBYISAFE
| Q4 25 | $216.3M | $7.2B | ||
| Q3 25 | $202.9M | $7.1B | ||
| Q2 25 | $194.9M | $7.1B | ||
| Q1 25 | $196.2M | $6.9B | ||
| Q4 24 | $213.3M | $6.9B | ||
| Q3 24 | $220.7M | $6.8B | ||
| Q2 24 | $205.0M | $6.8B | ||
| Q1 24 | $214.1M | $6.7B |
负债/权益比PBYISAFE
| Q4 25 | 0.17× | 1.90× | ||
| Q3 25 | 0.30× | 1.89× | ||
| Q2 25 | 0.43× | 1.87× | ||
| Q1 25 | 0.58× | 1.85× | ||
| Q4 24 | 0.74× | 1.84× | ||
| Q3 24 | 1.12× | 1.88× | ||
| Q2 24 | 1.87× | 1.81× | ||
| Q1 24 | 2.00× | 1.81× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $47.8M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | — |
| 自由现金流率自由现金流/营收 | 19.1% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | 1.72× |
| 过去12个月自由现金流最近4个季度 | $41.7M | — |
8季度趋势，按日历期对齐
经营现金流PBYISAFE
| Q4 25 | $14.4M | $47.8M | ||
| Q3 25 | $9.7M | $-1.4M | ||
| Q2 25 | $14.1M | $28.0M | ||
| Q1 25 | $3.6M | $8.9M | ||
| Q4 24 | $15.6M | $37.9M | ||
| Q3 24 | $11.0M | $8.3M | ||
| Q2 24 | $1.0M | $24.8M | ||
| Q1 24 | $11.2M | $-3.1M |
自由现金流PBYISAFE
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | — | ||
| Q2 25 | $14.1M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | — | — |
自由现金流率PBYISAFE
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | — | — |
资本支出强度PBYISAFE
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
现金转化率PBYISAFE
| Q4 25 | — | 1.72× | ||
| Q3 25 | 1.10× | -0.05× | ||
| Q2 25 | 2.41× | 1.00× | ||
| Q1 25 | 1.21× | 0.30× | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | 0.54× | 0.43× | ||
| Q2 24 | — | 0.83× | ||
| Q1 24 | — | -0.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBYI
暂无分部数据
SAFE
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $60.3M | 62% |
| Other | $33.7M | 34% |
| Stabilized Properties | $3.8M | 4% |
